Thursday - June 29, 2017

Bayer contributes to NHS transformation through innovative joint working projects in 2016

Shared projects have included infrastructure and equipment collaboration, staff secondments bringing specific business expertise and communications support

Reading, UK, 29 June 2017: Bayer UK’s pharmaceutical division is proud to publish a retrospective of its joint working projects with the NHS, the first ‘annual report’ of its kind to draw together the successes and enterprise seen over the course of 2016.


Joint working describes situations where, for the benefit of patients, NHS and industry organisations pool skills, experience and resources for the joint development and implementation of projects. Importantly, all parties share a commitment to successfully deliver direct and measurable patient benefits through these projects. Many NHS organisations recognise that joint working with partners who can supplement their own skills and resources can provide benefits that are not otherwise achievable.


Dr Alexander Moscho, CEO Bayer UK, supports our joint working successes in 2016: “At Bayer we are committed to delivering science for a better life – it drives everything we do and strengthens the pillars upon which we strive to build future relationships. Within the UK pharmaceutical division, we believe a key element of this commitment, of our Passion for Patients, is partnering with organisations to deliver projects with a direct and measurable benefit to patient care. Our 2016 Joint Working Report takes a short look at our vision for joint working and a review of our projects over the course of the past year, which we hope will also help to inspire future collaborations.”


Bayer supplies medicines that can reduce morbidity, increase survival and improve the quality of patients’ lives. Our contribution to national joint working projects is driven through skills and expertise arising from extensive experience in business and financial management and our knowledge of the therapy areas relevant to our medicines.


Commenting on the potential advantages and impact of working in collaboration with NHS partners, Amanda Cunnington, Head of Patient Access, Bayer UK, says: “The NHS faces many challenges yet maintains a ceaseless drive for improved quality and productivity in the system. At Bayer we are increasingly aware of the desire for external expertise to enable NHS organisations to meet these challenges, recognising that joint working with partners can supplement skills and resources, providing benefits for patients and the system that may not be otherwise achievable.”


Bayer is committed to long term joint working to improve patient outcomes and has already committed over £1.7million in 2017 and has seen many projects develop subsequent phases and secondary ideas which have been scoped and acted upon. The company looks forward to our ongoing projects and updates as the results are seen by the NHS partners we work with.


For more information or to request a copy of the report, contact:
Hayley Knight, Bayer Media Relations
Tel: 0118 206 3523 / 07788 365833


Notes to editors:
Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to


Bayer media team: 0118 206 3000
Hayley Knight, Bayer Media Relations: 0118 206 3523 / 07788 365833


Bayer’s offices in the UK and Ireland are located in Reading (head office), Cambridge and Dublin. For more information, go to
Follow us on Twitter at:
Follow us on Facebook
Follow us on YouTube at:


Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.